Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.51 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.51 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.51 |
| ▸ | KCNQ3 | O43525 | 4/20 | 0.50 |
| ▸ | KCNQ2 | O43526 | 4/20 | 0.50 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.50 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.50 |
| ▸ | BACE1 | P56817 | 1/20 | 0.50 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | KDM5A | P29375 | 1/20 | 0.46 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3120279 | 0.92 | RAB9A (0.57) | P4HTMRAB9ACYP1A2CYP2C19L3MBTL1 | |
| SCHEMBL3117348 | 0.90 | SMN1; SMN2 (0.58) | KCNQ3KCNQ2KCNE1KCNQ1RAB9A | |
| SCHEMBL3116564 | 0.90 | PTPN1 (0.50) | PTPN1KCNQ3KCNQ2P4HTMRAB9A | |
| SCHEMBL3117708 | 0.89 | KCNQ3 (0.56) | KCNQ3KCNQ2KCNE1KCNQ1RAB9A | |
| SCHEMBL3117290 | 0.89 | TRPV1 (0.47) | RAB9ACYP1A2CYP2C19L3MBTL1KMT2A | |
| SCHEMBL3116048 | 0.88 | P4HTM (0.54) | P4HTMRAB9ACYP1A2CYP2C19L3MBTL1 | |
| SCHEMBL3107074 | 0.87 | CYP11B1 (0.46) | RAB9ACYP1A2CYP2C19L3MBTL1KMT2A | |
| SCHEMBL3122154 | 0.87 | LMNA (0.52) | RAB9AKMT2AMAPTSMN1; SMN2NPC1 | |
| SCHEMBL3121975 | 0.84 | P4HTM (0.52) | PTPN1P4HTMRAB9ACYP1A2L3MBTL1 | |
| SCHEMBL14609473 | 0.83 | ULK1 (0.47) | KCNQ3KCNQ2KCNE1KCNQ1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179161-A1 | PYRAZOLINE DERIVATIVES FOR THE TREATMENT OF TURBERCULOSIS | ASTRAZENECA AB (SE) | 2010-07-15 | — | — | US | disclosed |
| US-20100179161-A1 | PYRAZOLINE DERIVATIVES FOR THE TREATMENT OF TURBERCULOSIS | ASTRAZENECA AB (SE) | 2010-07-15 | — | — | US | disclosed |
| US-20100179161-A1 | PYRAZOLINE DERIVATIVES FOR THE TREATMENT OF TURBERCULOSIS | ASTRAZENECA AB (SE) | 2010-07-15 | — | — | US | disclosed |
| CN-101291923-A | Pyrazolone derivatives for the treatment of tuberculosis | ASTRAZENECA AB (SE) | 2008-10-22 | — | — | CN | disclosed |
| EP-1919890-A1 | PYRAZOLONE DERIVATIVES FOR THE TREATMENT OF TUBERCULOSIS | AstraZeneca AB (SE) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007020426-A1 | PYRAZOLONE DERIVATIVES FOR THE TREATMENT OF TUBERCULOSIS | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179161-A1 | PYRAZOLINE DERIVATIVES FOR THE TREATMENT OF TURBERCULOSIS | TREH, TYMP, EPX | PTPN1 4503/4885PTPN6 4723/4885PTPN11 4434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.